Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report

ESC Heart Failure

Volumn 4, Issue 4, 2017, Pages 645-648

  Narang, Nikhil ^a   Medvedofsky, Diego ^a   Dryer, Kathryn ^b   Shah, Sanjiv J ^c   Davidson, Charles J ^d   Patel, Amit R ^a   Blair, John E A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NONE

Author keywords

Heart failure with preserved ejection fraction; Microvascular dysfunction

Indexed keywords

MONOXERUTIN;

CARDIAC MUSCLE; CARDIOMYOPATHY; CASE REPORT; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FIBROSIS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; LUNG WEDGE PRESSURE; MICROCIRCULATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOMYOPATHIES; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FIBROSIS; HEART FAILURE; HUMANS; HYDROXYETHYLRUTOSIDE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIUM; PULMONARY WEDGE PRESSURE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85049886547     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12170     Document Type: Article

References (15)

1. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Get with the Guidelines Scientific Advisory C, Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65–75.
2. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med 2016; 375: 1868–1877.
3. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, Bartz TM, Santhanakrishnan R, Lee DS, Chan C, Liu K, Blaha MJ, Hillege HL, van der Harst P, van Gilst WH, Kop WJ, Gansevoort RT, Vasan RS, Gardin JM, Levy D, Gottdiener JS, de Boer RA, Larson MG. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail 2016; 9: pii: e003116.
4. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131: 550–559.
5. Baumgart D, Haude M, Liu F, Ge J, Goerge G, Erbel R. Current concepts of coronary flow reserve for clinical decision making during cardiac catheterization. Am Heart J 1998; 136: 136–149.
6. Aarnoudse W, van den Berg P, van de Vosse F, Geven M, Rutten M, Van Turnhout M, Fearon W, de Bruyne B, Pijls N. Myocardial resistance assessed by guidewire-based pressure-temperature measurement: in vitro validation. Catheter Cardiovasc Interv 2004; 62: 56–63.
7. Yang HM, Khush K, Luikart H, Okada K, Lim HS, Kobayashi Y, Honda Y, Yeung AC, Valantine H, Fearon WF. Invasive assessment of coronary physiology predicts late mortality after heart transplantation. Circulation 2016; 133: 1945–1950.
8. Lee JM, Jung JH, Hwang D, Park J, Fan Y, Na SH, Doh JH, Nam CW, Shin ES, Koo BK. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol 2016; 67: 1158–1169.
9. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 49: 972–981.
10. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009; 2: 356–364.
11. Rommel KP, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lucke C, Gutberlet M, Linke A, Schuler G, Lurz P. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2016; 67: 1815–1825.
12. Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Dungen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM, Wachter R. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 2011; 100: 755–764.
13. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–271.
14. Borbely A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009; 104: 780–786.
15. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011; 4: 44–52.